Buz Investors DEA Schedules Insys Therapeutics’ Syndros Insys Therapeutics, Inc. (INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II

$INSY DEA Schedules Syndros (dronabinol oral solution) as Schedule II Drug

36px) Fz(25px)--sm Fz(32px) Mb(17px)--sm Mb(20px) Mb(30px)--lg Ff($ff-primary) Lts($lspacing-md) Fw($fweight) Fsm($fsmoothing) Fsmw($fsmoothing) Fsmm($fsmoothing) Wow(bw)" data-reactid="3">DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug

Buz Investors DEA Schedules Insys Therapeutics’ Syndros Insys Therapeutics, Inc. <span data-recalc-dims=(INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II" width="300" height="119" srcset="https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/03/insys-therapeutics-office.jpg?resize=300%2C119 300w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/03/insys-therapeutics-office.jpg?resize=768%2C306 768w, https://i0.wp.com/investorsbuz.com/wp-content/uploads/2017/03/insys-therapeutics-office.jpg?w=791 791w" sizes="(max-width: 300px) 100vw, 300px" />

Buz Investors DEA Schedules Insys Therapeutics’ Syndros  Insys Therapeutics, Inc. (INSY) (“Insys” or the “Company”) today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act.

On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros.

Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer, stated, “Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia associated weight loss, respectively.”





DEA Schedules Insys Therapeutics’ Syndros

“We look forward to interacting with the FDA to finalize the labeling and subsequent launch of Syndros in the second half of 2017,” concluded Vetticaden.

Important Safety Information

Syndros is a cannabinoid indicated in adults for the treatment of:

    40px) Mt(1.5em) Mb(1.5em) List(d)" data-type="list" data-reactid="11">
  • Anorexia associated with weight loss in patients with AIDS, and
  • Nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments

The use of dronabinol may cause psychiatric and cognitive effects and impair mental and/or physical abilities.
Patients with cardiac disorders may experience hypotension, hypertension, syncope or tachycardia.
May cause disulfiram-like reaction.
Weigh the potential risk versus benefits before prescribing Syndros to patients with a history of seizures, including those requiring anti-epileptic medication or other factors that lower the seizure threshold.
Assess risk for abuse or misuse in patients with a history of substance abuse or dependence, prior to prescribing Syndros and monitor for the development of associated behaviors or conditions.
Consider dose reduction or discontinuation, if worsening of symptoms while on treatment.
The safety and effectiveness of Syndros have not been established in pediatric patients.

About Insys Therapeutics, Inc.

Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need.

SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc.


Ebates Coupons and Cash Back



Pharmaceuticals  stocks ( CGC)  ( JNJ ) ( MRK ) ( GSK ) ( celg )  ( gild )



Minecoin Completes First Stage of ICO Ahead of Schedule

Minecoin Completes First Stage of ICO Ahead of Schedule

Minecoin Completes First Stage of ICO Ahead of Schedule

MinexSystems, creator of Minecoin cryptocurrency has announced the completion of ICO’s first stage much before the scheduled date.

Minecoin Completes First Stage of ICO Ahead of Schedule
Minecoin

Minecoin December 16, 2016, Kyiv, Ukraine – MinexSystems has successfully completed the first stage of its ICO, thanks to a commercial bank that acquired rest of the minecoin cryptocurrency. The bank’s participation has allowed MinexSystems to complete the ICO ahead of schedule.

During the talks between MinexSystems and commercial banks’ representatives, which were conducted within the last 2 months (according to the terms of the agreement, MS can not disclose the bank’s name before the transaction completion), MinexSystems have reached an accord regarding cooperation between MinexBank and one of the leading European banks. To acquire a share in the nominal capital of Minex Bank, the partner bank shall acquire the remaining coins. Therefore, all the unsold coins, that is 1095275.5 MNC are frozen, and currently minecoins can not be bought.

Partner bank buys 1095275.5 MNC, which weren’t sold during the subscription for 1705.44 BTC .

According to the results of voting, which was held on October 12 and was aimed at determining the bank’s model, a lot of participants has given their votes for a hybrid model, making the following arguments:

  • «Although I believe 100% in mathematics and perfection, it seems that some you run must be controlled by a human mind, the mind of its creators. best regards»
  • «If the algorithm has a big error, the human bin can correct it at least»
  • «For me it has to be human intelligence to adapt the system to the different scenarios as they arise. Human intelligence can discover new problems.”
  • «Nothing is flawless so every system needs a screening control»
  • «It feels a lot safer for me if some functions are regulated by humans»

According to the agreement, the partner bank shall close the deal before March 15, 2017, that is why MinexSystems is rescheduling the second stage of ICO for the early spring.

For those investors, who have already purchased coins and want to realize them, the developers have activated the function of coin transfer, opening in such a way, the OTC market, since there are no coins for sale.

For safety reasons, developers recommend everybody who have already bought minecoins, to change password and activate two-factor authorization in their personal accounts, in the ‘Settings’ tab.

In addition, on its official blog MS summarizes the results of its work since the beginning of the first ICO stage:

Results of the first stage (subscription)

Participation in the Blockchain conference
minecoin-blockchain-conference

“During the participation in the international blockchain conference, we have presented our idea to a wide audience from different countries. It gave us an opportunity to attract investment to the project, invite professionals of the field to join our team, get feedbacks and recommendations from blockchain industry experts. And the most important thing was to take acknowledgement of the idea efficiency and market demand in this project”.

Blockchain Hackathon
minecoin-hackathon

“During participation in this competition, the essence of which was to create a useful blockchain-based product in a short period of time, the members of MinexSystems team became the winners, proving the fact that they can see the existing market demands and create efficient solutions.”

MinexExchange
minecoin-minexexchange

“During this period, we have developed a platform for crypto assets trade. On October 29 there was a beta testing of the product, during which a beta version of MinexExchange was presented. Within the beta testing, developers received feedbacks and recommendations that should be applied to make the exchange more functional and user-friendly.”

Negotiations with bank

“During the negotiations with a commercial bank, we have agreed that the Partner bank will buy the remaining coins as part of acquiring a share in the nominal capital of MinexBank. In order to promote the growth of MinexBank, we are ready to work with a group of banks, and not just with one of them. Therefore, we intend to increase the number of banks that will be co-founders of MinexBank, adopting their experience regarding operation on the credit markets and making MB more decentralized.”

Fundraising

“Summing up the result of the subscription stage, it can be said that during the first stage of ICO we have collected 1176.56 Bitcoins. We thank all those who shared the idea and supported the development of the project by buying minecoins when the idea was at an early conceptualization stage only.Thus, we can say that we have achieved a lot during the short period of time. With each passing day we are becoming more experienced, our team is growing, and the number of those supporting the idea is increasing exponentially. We are confident that 2017 will be the year of MineCoin. Subscribe to our newsletter and social networks on the main page and stay informed about the development of the project”.

About Minex Systems

MinexSystems is a Ukrainian company that develops blockchain-based applications.
MinexSystems target is to make blockchain technology to serve society through the creation of targeted applications where this technology (blockchain) has practical applications.
Products of the company: MineCoin, Minex Bank, MinexPlatform, MinexExchange, MinexMarket.

Learn more about Minex Ecosystem at – www.minecoin.org

Cloud Peak Energy Inc. Announces Schedule for Third Quarter and First Nine Months of 2016 Results

Cloud Peak Energy Inc. Announces Schedule for Third Quarter and First Nine Months of 2016 Results

Cloud Peak Energy Inc Cloud Peak Energy In. Announces Schedule for Third Quarter and First Nine Months of 2016 Results

NYSE:
CLD
 Cloud Peak Energy Inc. Announces Schedule for Third Quarter and First Nine Months of 2016 Results

GILLETTE, Wyo.Cloud Peak Energy Inc. (NYSE:CLD), one of the largest U.S. coal producers and the only pure-play Powder River Basin (“PRB”) coal company, plans to announce its third quarter and first nine months of 2016 financial results on October 27, 2016, after the markets close.

A conference call with management is scheduled at 5:00 p.m. ET on October 27, 2016 to review the results and current business conditions. The call will be webcast live over the Internet from our website at www.cloudpeakenergy.com under “Investor Relations”. Participants should follow the instructions provided on the website for downloading and installing the audio applications necessary to join the webcast. Interested individuals also can access the live conference call via telephone at (855) 793-3260 (domestic) or (631) 485-4929 (international) and entering pass code 87708100.

Following the live webcast, a replay will be available at the same URL on our website for seven days. A telephonic replay will also be available approximately two hours after the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international) and entering pass code 87708100. The telephonic replay will be available for seven days.

About Cloud Peak Energy®

Cloud Peak Energy Inc. (NYSE:CLD) is headquartered in Wyoming and is one of the largest U.S. coal producers and the only pure-play Powder River Basin coal company. As one of the safest coal producers in the nation, Cloud Peak Energy mines low sulfur, subbituminous coal and provides logistics supply services. The Company owns and operates three surface coal mines in the PRB, the lowest cost major coal producing region in the nation. The Antelope and Cordero Rojo mines are located in Wyoming and the Spring Creek Mine is located in Montana. In 2015, Cloud Peak Energy shipped approximately 75 million tons from its three mines to customers located throughout the U.S. and around the world. Cloud Peak Energy also owns rights to substantial undeveloped coal and complimentary surface assets in the Northern PRB, further building the Company’s long-term position to serve Asian export and domestic customers. With approximately 1,400 total employees, the Company is widely recognized for its exemplary performance in its safety and environmental programs. Cloud Peak Energy is a sustainable fuel supplier for approximately three percent of the nation’s electricity.